Rhopressa
Active Ingredient(s): Netarsudil DimesylateFDA Approved: * December 18, 2017
Pharm Company: * AERIE PHARMS INC
Category: Vision / Eye Health
* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".
Rhopressa Overview
Netarsudil (trade name Rhopressa) is a drug for the treatment of glaucoma. In the United States, the Food and Drug Administration has approved a 0.02% ophthalmic solution for the lowering of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.[1] References ^ "Aerie (AERI) Gets Early FDA Approval for Lead Drug Rhopressa". December 19, 2017..mw-parser-output cite.citation{font-style:inherit}.mw-parser-output q{quotes:"\"""\"""'""'"}.m...
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Netarsudil
Recent Rhopressa Forums:
Be the first to start a discussion about this drug.Possible Dosages for this and Related Drugs:
Netarsudil Dimesylate
- Solution/drops: 0.02%
NDC Database Records for Rhopressa: (1 result)
Sorted by National Drug Code- 70727-497 Rhopressa .285 mg/ml Ophthalmic; Topical Solution/ Drops by Aerie Pharmaceuticals Inc.